AGO2 and ovarian carcinoma: Future investigations should focus on quantifying protein levels and activities of FN-1 and CXCL8, identifying the direct and critical targets of miR-101-3p in different ovarian cancer cell contexts through techniques like Ago2-RIP-Seq and luciferase reporter assays, and validating these findings in vivo.